Prab: CSV import

2024-03-06T04:22:56Z

CSV import

New page

[[File:Febuxostat.png|thumb|{{PAGENAME}}]]<br>'''Febuxostat''' is a [[non-purine selective inhibitor]] of [[xanthine oxidase]] that is used in the treatment of [[hyperuricemia]] and its complications, including chronic [[gout]]. It was developed by [[Takeda Pharmaceutical Company]] and was approved for use in the United States by the [[Food and Drug Administration]] (FDA) in 2009.

== Mechanism of Action ==

Febuxostat works by inhibiting the enzyme xanthine oxidase, which is involved in the production of [[uric acid]] in the body. By blocking this enzyme, febuxostat reduces the amount of uric acid produced, thereby preventing the formation of uric acid crystals that can cause gout.

== Clinical Use ==

Febuxostat is used primarily in the treatment of chronic gout and hyperuricemia. It is particularly useful in patients who are intolerant to [[allopurinol]], or in whom allopurinol is contraindicated. Febuxostat is also used in the management of tumor lysis syndrome, a condition that can occur in patients with certain types of cancer.

== Side Effects ==

Common side effects of febuxostat include liver function abnormalities, nausea, joint pain, and rash. In rare cases, febuxostat can cause serious side effects, including severe skin reactions and an increased risk of heart-related death.

== Contraindications ==

Febuxostat is contraindicated in patients with a history of hypersensitivity to febuxostat or any of its components. It is also contraindicated in patients being treated with azathioprine or mercaptopurine, as the concomitant use of these drugs with febuxostat can lead to serious or even fatal drug interactions.

== See Also ==

* [[Gout]]
* [[Hyperuricemia]]
* [[Xanthine oxidase]]
* [[Allopurinol]]
* [[Takeda Pharmaceutical Company]]

[[Category:Drugs]]
[[Category:Gout]]
[[Category:Hyperuricemia]]
[[Category:Xanthine oxidase inhibitors]]
{{pharmacology-stub}}

Febuxostat - Revision history

Prab: CSV import